drugset
Drugs / LOAd703
last change Feb 2026 re-read 3 minutes ago

LOAd703

Developed for
colorectal cancer · bile duct carcinoma · ovarian cancer · pancreatic adenocarcinoma
Investigated by
Hoffmann-La Roche · Lokon Pharma AB · Uppsala University

Trials 2

today NCT03555149 · Ph 1/2 NCT03225989 · Ph 1/2
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03555149 Sep 2018 → Sep 2022 colorectal cancer Hoffmann-La Roche Terminated No outcome recorded Stop: Enrollment
Phase 1/2 NCT03225989 Mar 2018 → Aug 2023 bile duct carcinoma, colorectal cancer, ovarian cancer, pancreatic adenocarcinoma Lokon Pharma AB Completed No outcome recorded

Press releases naming this drug 4 releases

DateIssuerRelease
2026-02-17 Lokon Pharma AB Results from first melanoma trial using LOAd703 tumor microenvironment gene engineering in combination with immune checkpoint inhibition is published in Nature Communications mynewsdesk.com ↗
2025-01-10 Lokon Pharma AB Lokon Pharma receives FDA Fast Track Designation for LOAd703 for the treatment of Pancreatic Cancer mynewsdesk.com ↗
2020-08-28 Lokon Pharma AB Lokon Pharma Expands Collaboration with Roche Evaluating LOAd703 Immunostimulatory Gene Cancer Therapy in Combination with Tecentriq® (atezolizumab) into Colorectal Cancer mynewsdesk.com ↗
2019-07-03 Lokon Pharma AB Lokon Pharma Announces Collaboration to Combine LOAd703 Oncolytic Virotherapy with Checkpoint Blockade in Pancreatic Cancer and Melanoma mynewsdesk.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as LOAd703 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03225989 ↗
1

NCT03555149 ↗
Route Other “LOAd703 is administered by intratumoral image-guided injections.” NCT03225989 ↗